Related Experiment Videos

Potent inhibition of human telomerase by nitrostyrene derivatives

Joo Hee Kim1, Jun Hyun Kim, Gun Eui Lee

  • 1DNA Link, Milk Building, Yonsei University, Seoul, Korea.

Molecular Pharmacology
|April 16, 2003
PubMed

Insights

Researchers identified a potent telomerase inhibitor, 3-(3,5-dichlorophenoxy)-nitrostyrene (DPNS), from a chemical library screen. DPNS selectively inhibits human telomerase, leading to cancer cell senescence and death, suggesting its potential for cancer chemotherapy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Telomerase is active in most cancer cells but not normal cells, making it a potential cancer chemotherapy target.
  • Inhibiting telomerase causes telomere shortening, leading to cancer cell growth arrest, senescence, or death.

Purpose of the Study:

  • To screen a chemical library for inhibitors of human telomerase.
  • To identify and characterize novel, selective telomerase inhibitors for potential cancer therapy.

Main Methods:

  • Chemical library screening for telomerase inhibition.
  • Enzyme kinetic studies to determine inhibition type and mechanism.
  • Cell-based assays to assess telomere length and senescence induction.

Main Results:

  • Identified three nitrostyrene-containing compounds that inhibit human telomerase.
  • 3-(3,5-dichlorophenoxy)-nitrostyrene (DPNS) demonstrated potent inhibition (IC50 ≈ 0.4 μM) without affecting other polymerases.
  • DPNS acts as a mixed-type noncompetitive inhibitor, binding to a site distinct from substrate and nucleotide binding sites.
  • DPNS treatment led to progressive telomere erosion and induced senescence in cancer cell lines.

Conclusions:

  • DPNS is a highly selective, small-molecule inhibitor of human telomerase in vitro.
  • DPNS exhibits a unique noncompetitive inhibition mechanism.
  • DPNS shows promise as a lead compound for developing novel cancer therapeutics targeting telomerase.

Related Concept Videos